Skip to content

Study · Randomized controlled trial · 2023

3 results

Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.

Stenlid R, Cerenius SY, Manell H, Küçükemre Aydin B, Mörwald K, Gomahr J, Höghammar Mitkas M, Eriksson I, Ciba I, Geiersberger S, Thivel D, Weghuber D, Bergsten P, Forslund A

Annals of nutrition & metabolism26 Oct 2023Cited by 4 (Europe PMC)

PMID37883939 (opens in a new tab)DOI10.1159/000534725 (opens in a new tab)PepBankPUB-37883939
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adolescents with obesity, 15 of 92 inflammatory proteins decreased and one increased following exenatide treatment, before adjustment for multiple testing.

    In plain wordsIn adolescents with obesity, 15 of 92 inflammatory proteins decreased and one increased after exenatide, before adjustment for multiple testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedInflammatory protein changes before adjustment
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg weekly · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Proteins decreased
    15 proteins
    of 92 measured, before multiple-testing adjustment
    Proteins increased
    1 proteins
    of 92 measured, before multiple-testing adjustment

    Source sentences

    Summary
    Following treatment with exenatide, 15 out of the 92 proteins were decreased, and one was increased.
    1 context sentence
    Summary · context
    Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adolescents with obesity, one inflammatory protein increased with exenatide before adjustment for multiple testing.

    In plain wordsIn adolescents with obesity, one inflammatory protein increased with exenatide before adjustment for multiple testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInflammatory protein increase before adjustment
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg weekly · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Following treatment with exenatide, 15 out of the 92 proteins were decreased, and one was increased.
    1 context sentence
    Summary · context
    Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adolescents with obesity, only IL-18Rα decreased significantly after exenatide treatment following adjustment for multiple testing.

    In plain wordsIn adolescents with obesity, only IL-18Rα decreased significantly with exenatide after adjustment for multiple testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseIL-18Rα after multiple-testing adjustment
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg weekly · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    However, after adjustment for multiple testing, only IL-18Rα was significantly lowered following treatment.
    1 context sentence
    Summary · context
    Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.